C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 4, 2000, Pages 1047-1051

  Gussekloo, Jacobijn ^a   Schaap, Marianne C L ^a   Frölich, Marijke ^a   Blauw, Gerard J ^a   Westendorp, Rudi G J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

C reactive protein; Cardiovascular diseases; Strokes; Survival

Indexed keywords

C REACTIVE PROTEIN;

AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GERIATRIC PATIENT; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; STROKE; SURVIVAL RATE;

EID: 0034075150     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.4.1047     Document Type: Article

References (22)

1. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol. 1996;144:537-547.
2. Haverkate F, Thompon SG, Pyke SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349:462-466.
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
4. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17:1121-1127.
5. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-733.
6. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. plasma concentrations of C-reactive protein and risk of developmg peripheral vascular disease. Circulation. 1998;97:425-428.
7. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk or coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839-844.
8. Koenig W, Sund M, Frolich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB. C-reactive protein a sensitive marker of inflammation predicts future risk of coronary heart disease in initially healthy middle-aged men: result, from the MONICA (monitoring trends and Determinants in Cardiovascular Disease) Ausburg Cohort Study, 1984 to 1992. Circulation. 1999;99:237-242.
9. Alexander RW. Inflammation and coronary artery disease. N Engl J Med. 1994;331:468-469.
10. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercelloti, GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82:513-520.
11. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007-2011.
12. Ridker PM. Inflammation, infection, and cardiovascular risk: how good is clinical evidence? Circulation. 1998;97:1671-1674.
13. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ. 1996;312:1061-1065.
14. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, Kuller LH. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997;17:2167-2176.
15. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RGJ. Total cholesterol and risk of mortality in the oldest old. Lancet. 1997;350:1119-1123.
16. Mackenbach JP, Kunst AE, Lautenbach H, Oei YB, Bijlsma F. Competing causes of death: a death certificate study. J Clin Epidemiol. 1997;50:1069-1077.
17. Deleted in proof.
18. Goldacre MJ. Cause-specific mortality: understanding uncertain tips of the disease iceberg. J Epidemiol Community Health. 1993;47: 491-496.
19. Heymans BT, Gussekloo J, Kluft C, Droog S, Lagaay AM, Knook DL, Westendorp RGJ, Slagboom PE. Increased risk of mortality associated with a common mutation in the methylenetetrahydrofolate reductase gene (MTHFR). Eur J Hum Genet. 1999;7:197-204.
20. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire community stroke project 1881-86, 2: incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 1988; 51:1373-1380.
21. Herman B, Leyten ACM, Luijck van JH, Frenken CWGM, Op de Coul AAW Schulte M. Epidemiology of stroke in Tilburg, the Netherlands: the population-based stroke incidence register, 2: incidence, initial clinical picture and medical care, and three-week case fatality. Stroke. 1982;13:692-635.
22. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506-512.